RTP Mobile Logo
Addressing Current Questions and Controversies in the Management of Prostate Cancer
Released March 2020

Proceedings from a CME symposium held at the 2020 Genitourinary Cancers Symposium. Featuring perspectives from Drs Emmanuel S Antonarakis, Andrew J Armstrong, Karim Fizazi and Matthew R Smith. (Video Program)

CE Disclosures and Faculty Information

    This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer (PC).


    • Appraise recent data on diagnostic and therapeutic advances in PC, and integrate this information, as appropriate, into current clinical care.
    • Evaluate the published research database supporting the recent FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant PC (CRPC), and apply this information in the discussion of nonresearch treatment options for these individuals.
    • Appraise the similarities and differences among commercially available next-generation antiandrogens in an effort to personalize therapeutic selection for individual patients.
    • Recognize the potential side effects associated with hormonal agents commonly employed in the management of PC, and develop strategies to prevent, mitigate and manage resultant toxicities.
    • Explore available data on the use of cytotoxic and secondary hormonal therapy in the setting of hormone-sensitive metastatic PC to effectively design treatment plans for appropriate individuals.
    • Apply evidence-based research findings in the determination of best-practice selection and sequencing of available local and systemic treatment modalities for patients with metastatic CRPC.
    • Describe the rationale for testing patients with metastatic PC for BRCA1/2 or other related mutations, and advise individuals found to harbor these genetic abnormalities about emerging Phase III data documenting the efficacy of PARP inhibition in appropriately selected individuals.
    • Recall the design of ongoing research studies evaluating other novel agents and strategies for PC, and counsel appropriate patients about availability and participation.

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and Research To Practice. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

    For questions about CME credit, either email continuinged@pennstatehealth.psu.edu or call (717) 531-6483 and reference course number G6598-20-T.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    It is the policy of Research To Practice and Penn State College of Medicine to ensure balance, independence, objectivity and scientific rigor in all their educational programs. All faculty, planners and managers participating in this activity are required to disclose any relevant financial relationship(s) they (or spouse/partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interest. Research To Practice and Penn State College of Medicine ensured that any conflicts of interest were resolved before the educational activity occurred.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Emmanuel S Antonarakis, MD
    Professor of Oncology and Urology
    Johns Hopkins University
    The Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland

    Consulting Agreements: Amgen Inc, Astellas, Clovis Oncology, Dendreon Pharmaceuticals Inc, ESSA Pharma Inc, Janssen Biotech Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Sanofi Genzyme; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Dendreon Pharmaceuticals Inc, Genentech, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Novartis, Sanofi Genzyme, Tokai Pharmaceuticals Inc; Other Remunerated Activities: Licensed patented technology to QIAGEN.

    Andrew J Armstrong, MD, ScM
    Professor of Medicine, Surgery, Pharmacology and Cancer Biology
    Director of Research
    Duke Cancer Institute Center for Prostate and Urologic Cancers
    Divisions of Medical Oncology and Urology
    Duke University
    Durham, North Carolina

    Advisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Merck; Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genomic Health Inc, Janssen Biotech Inc, Merck, Pfizer Inc, Tolero Pharmaceuticals; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, Genentech, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc.

    Karim Fizazi, MD, PhD
    Department of Cancer Medicine
    GETUG President
    Institut Gustave Roussy
    Professor in Oncology
    University of Paris-Sud
    Paris, France

    Advisory Committee: Astellas, Bayer HealthCare Pharmaceuticals, CureVac, Janssen Biotech Inc, Merck Sharp & Dohme Corp, Orion Corporation, Sanofi Genzyme.

    Matthew R Smith, MD, PhD
    Claire and John Bertucci Endowed Chair in Genitourinary Cancers
    Professor of Medicine
    Harvard Medical School
    Director, Genitourinary Malignancies Program
    Massachusetts General Hospital Cancer Center
    Boston, Massachusetts

    Advisory Committee and Consulting Agreements: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly; Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Janssen Biotech Inc, Lilly.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    PENN STATE COLLEGE OF MEDICINE — Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice and Penn State College of Medicine do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genomic Health Inc, Merck and Sanofi Genzyme.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: March 2020
    Expiration date: March 2021

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):